mRNA expression level of <em>CDH2, LEP, POSTN, TIMP1</em> and <em>VEGFC</em> modulates 5‑fluorouracil resistance in colon cancer cells

Liu,Tao; Xia,Rongmu; Li,Chenmeng; Chen,Xiaocong; Cai,Xuemin; Li,Wengang

doi:10.3892/etm.2021.10455

mRNA expression level of CDH2, LEP, POSTN, TIMP1 and VEGFC modulates 5‑fluorouracil resistance in colon cancer cells

Authors:
- Tao Liu
- Rongmu Xia
- Chenmeng Li
- Xiaocong Chen
- Xuemin Cai
- Wengang Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Xiang'an Hospital of Xiamen University, Xiamen, Fujian 361102, P.R. China, School of Medicine, Xiamen University, Xiamen, Fujian 361102, P.R. China, Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China
Published online on: July 15, 2021 https://doi.org/10.3892/etm.2021.10455
Article Number: 1023
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance severely affects the clinical efficacy of therapeutic agents in patients with colon cancer. The aim of the present study was to identify genes involved in drug resistance in colon cancer using bioinformatics analysis and to identify the underlying mechanisms in vitro. Genes associated with cancer recurrence and chemotherapy resistance were identified using data mining. Immunohistochemistry was performed to analyze the protein expression level of genes of interest in human colon cancer tissues. Reverse transcription‑quantitative PCR analysis was performed to analyze the gene expression level in patient samples and in colon cancer cell lines (HCT116 and LoVo). Cell viability was evaluated using the Cell Counting Kit‑8 assay in the colon cancer cell lines. Apoptosis was measured using PI staining. The results from the present study revealed 602 genes using both ‘cancer recurrence’ and ‘chemoresistance’ terms on the GenCLiP3 website. Gene functional annotation was performed using the Database for Annotation, Visualization and Integrated Discovery then, the protein‑protein interaction networks of the 602 genes were analyzed using STRING analysis. Further, in the GEPIA database, 14 genes (ATM, CDH2, CDKN2A, EPO, LEP, TGFB1, TIMP1, PGR, VEGFC, POSTN, BCL6, CYP19A1, NOTCH3 and XPA) were found to be upregulated in colon cancer tissue and were associated with poor prognosis in patients with colon cancer. Further analysis of 33 paired human colon cancer tissues revealed that 8 genes (ATM, CDH2, CDKN2A, LEP, PGR, TIMP1, POSTN and VEGFC) were significantly upregulated, which was consistent with the results obtained from the earlier analysis and 5 genes (CDH2, LEP, POSTN, TIMP1 and VEGFC) were associated with patient prognosis. Silencing of these 5 genes using small interfering RNAs significantly enhanced the sensitivity of colon cancer cells to the chemotherapeutic agent, 5‑fluorouracil (5‑FU). Taken together, the results suggested that CDH2, LEP, POSTN, TIMP1 and VEGFC might play a role in chemotherapeutic resistance in colon cancer and represent potential targets for overcoming 5‑FU resistance in colon cancer.

View Figures

View References

1	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013.PubMed/NCBI View Article : Google Scholar
2	Vasan N, Baselga J and Hyman DM: A view on drug resistance in cancer. Nature. 575:299–309. 2019.PubMed/NCBI View Article : Google Scholar
3	Zhu H, Luo H, Zhang W, Shen Z, Hu X and Zhu X: Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 10:1885–1895. 2016.PubMed/NCBI View Article : Google Scholar
4	Nikolaou M, Pavlopoulou A, Georgakilas AG and Kyrodimos E: The challenge of drug resistance in cancer treatment: A current overview. Clin Exp Metastasis. 35:309–318. 2018.PubMed/NCBI View Article : Google Scholar
5	Panda M and Biswal BK: Cell signaling and cancer: A mechanistic insight into drug resistance. Mol Biol Rep. 46:5645–5659. 2019.PubMed/NCBI View Article : Google Scholar
6	Salgia R and Kulkarni P: The genetic/non-genetic duality of drug ‘resistance’ in cancer. Trends Cancer. 4:110–118. 2018.PubMed/NCBI View Article : Google Scholar
7	Kartal-Yandim M, Adan-Gokbulut A and Baran Y: Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 36:716–726. 2016.PubMed/NCBI View Article : Google Scholar
8	Chatterjee N and Bivona TG: Polytherapy and Targeted Cancer Drug Resistance. Trends Cancer. 5:170–182. 2019.PubMed/NCBI View Article : Google Scholar
9	Hirose M, Hosoi E, Hamano S and Jalili A: Multidrug resistance in hematological malignancy. J Med Invest. 50:126–135. 2003.PubMed/NCBI
10	Hackl H, Astanina K and Wieser R: Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 10(51)2017.PubMed/NCBI View Article : Google Scholar
11	Waghray D and Zhang Q: Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem. 61:5108–5121. 2018.PubMed/NCBI View Article : Google Scholar
12	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
13	Wu C: Systemic therapy for colon cancer. Surg Oncol Clin N Am. 27:235–242. 2018.PubMed/NCBI View Article : Google Scholar
14	Hu T, Li Z, Gao CY and Cho CH: Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 22:6876–6889. 2016.PubMed/NCBI View Article : Google Scholar
15	Han B, Feng D, Yu X, Zhang Y, Liu Y and Zhou L: Identification and interaction analysis of molecular markers in colorectal cancer by integrated bioinformatics analysis. Med Sci Monit. 24:6059–6069. 2018.PubMed/NCBI View Article : Google Scholar
16	Irham LM, Wong HS, Chou WH, Adikusuma W, Mugiyanto E, Huang WC and Chang WC: Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Pharmacol Res. 161(105203)2020.PubMed/NCBI View Article : Google Scholar
17	Zhang X, Zhang H, Shen B and Sun XF: Novel MicroRNA biomarkers for colorectal cancer early diagnosis and 5-fluorouracil chemotherapy resistance but not prognosis: A atudy from databases to AI-assisted verifications. Cancers (Basel). 12(E341)2020.PubMed/NCBI View Article : Google Scholar
18	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A (eds): AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, 2010.
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Li Q, Lai Z, Yan Z, Peng J, Jin Y, Wei L and Lin J: Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5 FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway. Mol Med Rep. 17:358–365. 2018.PubMed/NCBI View Article : Google Scholar
21	Li Q, Wei L, Lin S, Chen Y, Lin J and Peng J: Synergistic effect of kaempferol and 5 fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. Mol Med Rep. 20:728–734. 2019.PubMed/NCBI View Article : Google Scholar
22	Fallah J and Rini BI: HIF Inhibitors: Status of current clinical Development. Curr Oncol Rep. 21(6)2019.PubMed/NCBI View Article : Google Scholar
23	Feng X, Liu H, Zhang Z, Gu Y, Qiu H and He Z: Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. J Exp Clin Cancer Res. 36(123)2017.PubMed/NCBI View Article : Google Scholar
24	Zhao F and Lam EW: Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med. 6:376–380. 2012.PubMed/NCBI View Article : Google Scholar
25	Lai M, Liu G, Li R, Bai H, Zhao J, Xiao P and Mei J: Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF-α pathway in human colon cancer. J Cell Mol Med. 24:5021–5027. 2020.PubMed/NCBI View Article : Google Scholar
26	Kozovska Z, Gabrisova V and Kucerova L: Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother. 68:911–916. 2014.PubMed/NCBI View Article : Google Scholar
27	Yuan Z, Shi X, Qiu Y, Jia T, Yuan X, Zou Y, Liu C, Yu H, Yuan Y, He X, et al: Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin. Oncol Rep. 37:1815–1825. 2017.PubMed/NCBI View Article : Google Scholar
28	Hu T, To KK, Wang L, Zhang L, Lu L, Shen J, Chan RL, Li M, Yeung JH and Cho CH: Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza. Phytomedicine. 21:1264–1272. 2014.PubMed/NCBI View Article : Google Scholar
29	Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, et al: Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. Front Pharmacol. 6(147)2015.PubMed/NCBI View Article : Google Scholar
30	Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, et al: miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol. 8:83–92. 2014.PubMed/NCBI View Article : Google Scholar
31	Alimperti S and Andreadis ST: CDH2 and CDH11 act as regulators of stem cell fate decisions. Stem Cell Res (Amst). 14:270–282. 2015.PubMed/NCBI View Article : Google Scholar
32	Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells. 8(E1118)2019.PubMed/NCBI View Article : Google Scholar
33	Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P, Theou-Anton N, et al: Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther. 9:1308–1317. 2010.PubMed/NCBI View Article : Google Scholar
34	Tomida C, Yamagishi N, Nagano H, Uchida T, Ohno A, Hirasaka K, Nikawa T and Teshima-Kondo S: VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells. Int J Oncol. 52:1350–1362. 2018.PubMed/NCBI View Article : Google Scholar
35	Zhang Y and Chua S Jr: Leptin function and regulation. Compr Physiol. 8:351–369. 2017.PubMed/NCBI View Article : Google Scholar
36	Lipsey CC, Harbuzariu A, Robey RW, Huff LM, Gottesman MM and Gonzalez-Perez RR: Leptin signaling affects survival and chemoresistance of estrogen receptor negative breast cancer. Int J Mol Sci. 21(E3794)2020.PubMed/NCBI View Article : Google Scholar
37	Lao G, Ren M, Wang X, Zhang J, Huang Y, Liu D, Luo H, Yang C and Yan L: Human tissue inhibitor of metalloproteinases-1 improved wound healing in diabetes through its anti-apoptotic effect. Exp Dermatol. 28:528–535. 2019.PubMed/NCBI View Article : Google Scholar
38	Lee JH, Choi JW and Kim YS: Serum TIMP-1 predicts survival outcomes of invasive breast carcinoma patients: A meta-analysis. Arch Med Res. 42:463–468. 2011.PubMed/NCBI View Article : Google Scholar
39	Tan Y, Li X, Tian Z, Chen S, Zou J, Lian G, Chen S, Huang K and Chen Y: TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Biochem Pharmacol. 189(114085)2021.PubMed/NCBI View Article : Google Scholar
40	Liu C, Feng X, Wang B, Wang X, Wang C, Yu M, Cao G and Wang H: Bone marrow mesenchymal stem cells promote head and neck cancer progression through Periostin-mediated phosphoinositide 3-kinase/Akt/mammalian target of rapamycin. Cancer Sci. 109:688–698. 2018.PubMed/NCBI View Article : Google Scholar
41	Xiao ZM, Wang XY and Wang AM: Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway. Biotechnol Appl Biochem. 62:401–406. 2015.PubMed/NCBI View Article : Google Scholar
42	Ratajczak-Wielgomas K, Kmiecik A, Grzegrzołka J, Piotrowska A, Gomulkiewicz A, Partynska A, Pawelczyk K, Nowinska K, Podhorska-Okolow M and Dziegiel P: Prognostic significance of stromal periostin expression in non-small cell lung cancer. Int J Mol Sci. 21(E7025)2020.PubMed/NCBI View Article : Google Scholar
43	Park SY, Piao Y, Jeong KJ, Dong J and de Groot JF: Periostin (POSTN) regulates tumor resistance to antiangiogenic therapy in glioma models. Mol Cancer Ther. 15:2187–2197. 2016.PubMed/NCBI View Article : Google Scholar